Bavarian Nordic initiates clinical trials of mpox vaccine in infants and pregnant women: Copenhagen, Denmark Saturday, June 28, 2025, 12:00 Hrs [IST] Bavarian Nordic A/S, a global ...

As Sierra Leone grapples with the rapid escalation of mpox cases, AIDS Healthcare Foundation (AHF) calls for urgent global action to improve vaccination efforts for the response, including Bavarian ...

Vaccine supply shortage comes at a bad time, as African countries make headway with their outbreaks and have seen good uptake ...

NACCHO selects 5 local health departments as mentors and 11 as mentees for the 2025 Wastewater Monitoring Mentorship Program.

Monkeypox Vaccine and Treatment revenue is expected to grow at a CAGR of 10.20% from 2025 to 2032, reaching nearly USD 225.12 Mn by 2032.

Bavarian Nordic AS BAVA Stock XCSE Rating as of Jul 1, 2025 More Actions Summary Chart News Price vs Fair Value Sustainability Trailing Returns Key Metrics Financials Valuation Dividends Ownership ...

A high-level overview of Bavarian Nordic A/S (BVNRY) stock. View (BVNRY) real-time stock price, chart, news, analysis, analyst reviews and more.

Bavarian Nordic is likely just weeks away from bringing the second chikungunya vaccine to the EU, and the first approved for use in adolescents.

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

MVA-BN vaccine shown to be safe and 84% effective against mpox in HIV-negative people. Real-world data support rollout in ...